hsa-miR-429

ncRNA information

ncRNA name

hsa-miR-429

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

ZEB1

Cancer information

Cancer name

Epithelial Ovarian Cancer

Cancer site

Ovary

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Up

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

72

Male patients

Not available

Female patients

Not available

Age range and number

38(<=50)+34(>50)

Research information

PMID

Description

Overexpression of miR-429 may suppress ZEB1, and may be a potential sensitizer to cisplatin treatment that may have therapeutic implications.

Tissue resource

epithelial ovarian cancer tissues

human epithelial ovarian carcinoma cell lines SKOV3

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the Affiliated Tumor Hospital of Guangxi Medical University

the Affiliated Tumor Hospital of Guangxi Medical University

Country

China

Continent

Asia